AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Sun pharma moneycontrol4/19/2023 Its focus is for NCEs, NBEs, NDDS based differentiated products, Biosimilars, Proprietary Technology Barrier Products which provide it the first mover advantage in India. These include CNS disorders, Cardiology, Diabetes and Metabolic disorders, Gastroenterology, Ophthalmology, Oncology, Pain, Rheumatology, Allergy, Asthma and Inflammation and Gynecology. The company is market leader in India and it is interested in partnerships for late stage and/or marketed opportunities complementary to its commercial footprint or expansion within its core areas of focus in India. The company’s primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets. It has an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia. It has strong capabilities in developing generic and complex products with a robust pipeline of many ANDAs, including high value First-to-File (FTF) opportunities. In the US market which contributes a significant share of its revenues, the company is the leader in the generic dermatology segment. Its global presence is supported by several manufacturing facilities across few continents. Sun Pharma is also India’s largest and pharmaceutical company. It provide high-quality, affordable medicines trusted by healthcare professionals and patients in many countries worldwide. Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. Sun Pharmaceutical Industries established in 1983 with five psychiatry products and a two person marketing team.
0 Comments
Read More
Leave a Reply. |